Novel immunotherapies using bi-specific monoclonal antibodies targeting the CD30 antigen present on HRS cells are currently evaluated as salvage treatment for patients with refractory or relapsed cHL [4, 20]. This evidence concerns the gene TNFRSF8 and classic Hodgkin lymphoma.